Table 2.

Menstrual outcomes.

Variables	Single‐layer closure (n = 1144)	Double‐layer closure (n = 1148)	Outcome measure	Adjusted effect estimate (95% CI)*	P
Postmenstrual spotting, days/month	n = 774	n = 770
Median (IQR)	0.0 (0.0–2.0)	0.0 (0.0–1.0)	Median difference	0.00 (−0.08 to 0.08)	1.0
Mean (SD)	1.33 (3.00)	1.26 (2.77)	Mean difference	−0.07 (−0.37 to 0.22)	0.810
Present at least one day per month	275/774 (35.5%)	264/770 (34.3%)	Relative risk Risk difference	0.96 (0.84 to 1.10) −0.01 (−0.06 to 0.04)	0.580 0.602
Total days blood loss, days/month	6.0 (3.5)	5.9 (3.0)	Mean difference	−0.1 (−0.4 to 0.3)	0.752
Duration of menstruation, days/month	5.5 (2.3)	5.7 (2.5)	Mean difference	0.1 (−0.1 to 0.4)	0.276
Dysmenorrhoea, scale 0–10	4.0 (2.0–6.0)	4.0 (2.0–6.0)	Median difference	0.0 (−0.4 to 0.4)	1.0
Need for treatment of gynaecological complaints**	13/913 (1.4%)	25/903 (2.8%)	Relative risk Risk difference	1.93 (0.99 to 3.75) 0.02 (0.00 to 0.03)	0.052
Lost to follow‐up	204 (17.8%)	212 (18.5%)	Relative risk Risk difference	1.04 (0.88 to 1.24) 0.01 (−0.03 to 0.04)	0.655 0.770
Amenorrhoea	166 (14.5%)	166 (14.5%)	Relative risk Risk difference	1.01 (0.83 to 1.22) 0.00 (−0.03 to 0.03)	0.952 0.997

Data are medians (IQRs), means (SDs) or n (%), unless otherwise indicated; 95% CI, 95% confidence interval; CS, caesarean section.

^*Adjusted for timing of CS.

^**Data available for 913 women in the single‐layer group and 903 women in the double‐layer group; complaints for abdominal pain or abnormal uterine bleeding, treatment could be medicinal, surgical, combined or ‘other’.

Postmenstrual spotting (mean and median) was primary outcome and all others were secondary outcomes.

Secondary outcomes. Confidence intervals and P values for mean difference in spotting days per month have been determined using bootstrapping. Effect estimates are calculated with single‐layer closure as the reference group.